As­traZeneca, Mer­ck score Chi­na OK for Lyn­parza; Re­gen­eron spot­lights mid-stage da­ta for rare dis­ease drug

→ As they con­tin­ue to scoop up wins for their PARP jug­ger­naut Lyn­parza, As­traZeneca — along with their part­ners at Mer­ck — have scored ap­proval in Chi­na as a first-line main­te­nance treat­ment for a form of ovar­i­an can­cer. Reg­u­la­tors based their de­ci­sion on re­sults from the SO­LO-1 tri­al, in which the drug low­ered the risk of dis­ease pro­gres­sion or death by 70% when com­pared to place­bo. It marks a ma­jor ad­di­tion to the list of 65 coun­tries in which Lyn­parza is ap­proved to treat plat­inum-sen­si­tive re­lapsed ovar­i­an can­cer, the com­pa­nies said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER